Ting Martin Ma
University of California, Los Angeles
RadiobiologyInternal medicineRadiologyOncologyAMPA receptorRetrospective cohort studyChemistryMedical physicsNeurotransmissionBiopsyProstateSerine racemaseSerineBrachytherapyDISC1Prostate cancerLymph nodeStereotactic body radiation therapyNuclear medicineRadiation therapyBiochemistryNMDA receptorMedicineBiologyCell biology
23Publications
10H-index
395Citations
Publications 28
Newest
#1Ting Martin Ma (UCLA: University of California, Los Angeles)H-Index: 10
#2Soumyajit Roy (Rush University Medical Center)
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 22
view all 27 authors...
Background and purpose null The Phoenix definition for biochemical failure (BCF) after radiotherapy uses nadir PSA (nPSA)+2ng/mL to classify a BCF and was derived from conventionally fractionated radiotherapy, which produces significantly higher nPSAs than stereotactic body radiotherapy (SBRT). We investigated whether an alternative nPSA-based threshold could be used to define post-SBRT BCFs. null Materials and methods null PSA kinetics data on 2038 patients from 9 institutions were retrospectiv...
Source
#1David Shabsovich (UCLA: University of California, Los Angeles)H-Index: 6
#2Michael Xiang (UCLA: University of California, Los Angeles)H-Index: 14
Last. Abigail Pepin (GW: George Washington University)H-Index: 3
view all 20 authors...
PURPOSE/OBJECTIVE(S) Stereotactic body radiation therapy (SBRT) has emerged as a promising modality for the treatment of prostate cancer (PCa) and involves the delivery of ablative doses of radiation to the prostate. The patterns of failure at the time of biochemical recurrence (BCR) after SBRT remain unknown. The purpose of this study is to explore the development of distant metastasis (DM) following the diagnosis of BCR. MATERIALS/METHODS We queried a multi-institutional database of 2,430 pati...
Source
#1Ting Martin Ma (UCLA: University of California, Los Angeles)H-Index: 10
#2Michael Xiang (UCLA: University of California, Los Angeles)H-Index: 14
Last. Jeffrey J. Tosoian (UM: University of Michigan)H-Index: 30
view all 20 authors...
PURPOSE/OBJECTIVE(S) Occult non-localized disease (N1 or M1) at the time of definitive treatment of high-risk prostate cancer (HR-PCa) underlies most treatment failures. We recently developed a nomogram tuned to the identification of non-localized disease on prostate specific membrane antigen PET/CT (PSMA PET/CT) in patients with cN0M0 HR-PCa by conventional imaging, which incorporates iPSA, percent positive core on biopsy, Gleason Grade and cT stage. We systematically compared the prognostic pe...
Source
#1Ting Martin Ma (UCLA: University of California, Los Angeles)H-Index: 10
#2Soumyajit Roy (NYMC: New York Medical College)H-Index: 10
Last. Rachel Glicksman (U of T: University of Toronto)H-Index: 7
view all 20 authors...
Purpose/Objective(s) null Since the seminal Phoenix definition (nadir PSA+2) of biochemical failure (BCF) was published in 2006, increasingly more patients with low- and intermediate-risk prostate cancer (PCa) are being treated with stereotactic body radiation therapy (SBRT). Since SBRT leads to lower nadir PSA (nPSA) compared to conventionally fractionated RT, we investigated if an earlier nPSA+threshold can be used as an alternative definition of BCF. null null null Materials/Methods null PSA ...
Source
#1A.U. Kishan (UCLA: University of California, Los Angeles)H-Index: 4
#2Yi Sun (UM: University of Michigan)H-Index: 83
Last. David Joseph (SCGH: Sir Charles Gairdner Hospital)H-Index: 63
view all 20 authors...
Purpose/Objective(s) null To conduct the first global individual patient data (IPD) meta-analysis of randomized trials to assess the impact of androgen deprivation therapy (ADT) use and duration with definitive radiotherapy (RT) in localized prostate cancer. null null null Materials/Methods null The MARCAP Consortium was formed from international trial groups (NRG/RTOG, EORTC, TROG, DART/GICOR, and ICORG). IPD for 10,131 patients enrolled across 11 RT trials were available for three pre-specifie...
Source
#1Neil R. ParikhH-Index: 4
Last. James Lamb (UCLA: University of California, Los Angeles)H-Index: 17
view all 11 authors...
Background and Purpose Stereotactic body radiation therapy (SBRT) has become a standard-of-care option for localized prostate cancer. While prostate SBRT has traditionally been delivered using computed-tomography-guided radiation therapy (CTgRT), MR-imaging-guided radiation therapy (MRgRT) is now available. MRgRT offers real-time soft-tissue visualization and ease of adaptive planning, obviating the need for fiducial markers, and potentially allowing for smaller planning target volume (PTV) marg...
#1Tommy Jiang (UCLA: University of California, Los Angeles)H-Index: 4
#2Daniela Markovic (UCLA: University of California, Los Angeles)H-Index: 26
Last. Matthew Rettig (UCLA: University of California, Los Angeles)H-Index: 43
view all 13 authors...
BACKGROUND While multiple randomized trials have evaluated the benefit of radiation therapy (RT) dose escalation and the use and prolongation of androgen deprivation therapy (ADT) in the treatment of prostate cancer, few studies have evaluated the relative benefit of either form of treatment intensification with each other. Many trials have included treatment strategies that incorporate either high or low dose RT, or short-term or long-term ADT (STADT or LTADT), in one or more trial arms. We sou...
Source
#1Ting Martin Ma (UCLA: University of California, Los Angeles)H-Index: 10
#2James Lamb (UCLA: University of California, Los Angeles)H-Index: 17
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 22
view all 13 authors...
BACKGROUND Stereotactic body radiotherapy (SBRT) is becoming increasingly used in treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy profiles when compared with longer courses of definitive radiation. Magnetic resonance imaging (MRI)-guided radiotherapy has multiple potential advantages over standard computed tomography (CT)-guided radiotherapy, including enhanced prostate visualization (abrogating the need for fiducials and MRI fusion), enhanced identi...
Source
#1David D. Yang (Harvard University)H-Index: 13
#2Edward Christopher Dee (Harvard University)H-Index: 7
Last. Vinayak Muralidhar (Brigham and Women's Hospital)H-Index: 18
view all 12 authors...
205Background: Commonly used tools for predicting the risk of pelvic lymph node involvement (LNI) in prostate cancer often do not incorporate information on the percentage of positive biopsy cores ...
Source
#1Boris R. Tocco (The Royal Marsden NHS Foundation Trust)H-Index: 2
#2Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 22
Last. Alison Tree (The Royal Marsden NHS Foundation Trust)H-Index: 22
view all 5 authors...
External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anato...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.